Alterations in the Rho pathway contribute to Epstein-Barr virus-induced lymphomagenesis in immunosuppressed environments
Cho, S.-Y., Sung, C. O., Chae, J., Lee, J., Na, D., Kang, W., Kang, J., Min, S., Lee, A., Kwak, E., Kim, J., Choi, B., Kim, H., Chuang, J. H., Pak, H.-K., Park, C.-S., Park, S., Ko, Y. H., Lee, D., Roh, J., Cho, M.-S., Park, S., Ju, Y. S., Suh, Y.-S., Kong, S.-H., Lee, H.-J., Keck, J., Banchereau, J., Liu, E. T., Kim, W.-H., Park, H., Yang, H.-K., Kim, J.-I., Lee, C.
American Society of Hematology (ASH)
Published 2018
American Society of Hematology (ASH)
Published 2018
| Publication Date: |
2018-04-27
|
|---|---|
| Publisher: |
American Society of Hematology (ASH)
|
| Print ISSN: |
0006-4971
|
| Electronic ISSN: |
1528-0020
|
| Topics: |
Biology
Medicine
|
| Keywords: |
Immunobiology and Immunotherapy, Lymphoid Neoplasia
|
| Published by: |
| _version_ | 1836398909500424192 |
|---|---|
| autor | Cho, S.-Y., Sung, C. O., Chae, J., Lee, J., Na, D., Kang, W., Kang, J., Min, S., Lee, A., Kwak, E., Kim, J., Choi, B., Kim, H., Chuang, J. H., Pak, H.-K., Park, C.-S., Park, S., Ko, Y. H., Lee, D., Roh, J., Cho, M.-S., Park, S., Ju, Y. S., Suh, Y.-S., Kong, S.-H., Lee, H.-J., Keck, J., Banchereau, J., Liu, E. T., Kim, W.-H., Park, H., Yang, H.-K., Kim, J.-I., Lee, C. |
| beschreibung | Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphomas (EBV + -DLBLs) tend to occur in immunocompromised patients, such as the elderly or those undergoing solid organ transplantation. The pathogenesis and genomic characteristics of EBV + -DLBLs are largely unknown because of the limited availability of human samples and lack of experimental animal models. We observed the development of 25 human EBV + -DLBLs during the engraftment of gastric adenocarcinomas into immunodeficient mice. An integrated genomic analysis of the human-derived EBV + -DLBLs revealed enrichment of mutations in Rho pathway genes, including RHPN2 , and Rho pathway transcriptomic activation. Targeting the Rho pathway using a Rho-associated protein kinase (ROCK) inhibitor, fasudil, markedly decreased tumor growth in EBV + -DLBL patient-derived xenograft (PDX) models. Thus, alterations in the Rho pathway appear to contribute to EBV-induced lymphomagenesis in immunosuppressed environments. |
| citation_standardnr | 6245167 |
| datenlieferant | ipn_articles |
| feed_id | 310 |
| feed_publisher | American Society of Hematology (ASH) |
| feed_publisher_url | http://www.hematology.org/ |
| insertion_date | 2018-04-27 |
| journaleissn | 1528-0020 |
| journalissn | 0006-4971 |
| publikationsjahr_anzeige | 2018 |
| publikationsjahr_facette | 2018 |
| publikationsjahr_intervall | 7984:2015-2019 |
| publikationsjahr_sort | 2018 |
| publisher | American Society of Hematology (ASH) |
| quelle | Blood |
| relation | http://www.bloodjournal.org/cgi/content/short/131/17/1931?rss=1 |
| schlagwort | Immunobiology and Immunotherapy, Lymphoid Neoplasia |
| search_space | articles |
| shingle_author_1 | Cho, S.-Y., Sung, C. O., Chae, J., Lee, J., Na, D., Kang, W., Kang, J., Min, S., Lee, A., Kwak, E., Kim, J., Choi, B., Kim, H., Chuang, J. H., Pak, H.-K., Park, C.-S., Park, S., Ko, Y. H., Lee, D., Roh, J., Cho, M.-S., Park, S., Ju, Y. S., Suh, Y.-S., Kong, S.-H., Lee, H.-J., Keck, J., Banchereau, J., Liu, E. T., Kim, W.-H., Park, H., Yang, H.-K., Kim, J.-I., Lee, C. |
| shingle_author_2 | Cho, S.-Y., Sung, C. O., Chae, J., Lee, J., Na, D., Kang, W., Kang, J., Min, S., Lee, A., Kwak, E., Kim, J., Choi, B., Kim, H., Chuang, J. H., Pak, H.-K., Park, C.-S., Park, S., Ko, Y. H., Lee, D., Roh, J., Cho, M.-S., Park, S., Ju, Y. S., Suh, Y.-S., Kong, S.-H., Lee, H.-J., Keck, J., Banchereau, J., Liu, E. T., Kim, W.-H., Park, H., Yang, H.-K., Kim, J.-I., Lee, C. |
| shingle_author_3 | Cho, S.-Y., Sung, C. O., Chae, J., Lee, J., Na, D., Kang, W., Kang, J., Min, S., Lee, A., Kwak, E., Kim, J., Choi, B., Kim, H., Chuang, J. H., Pak, H.-K., Park, C.-S., Park, S., Ko, Y. H., Lee, D., Roh, J., Cho, M.-S., Park, S., Ju, Y. S., Suh, Y.-S., Kong, S.-H., Lee, H.-J., Keck, J., Banchereau, J., Liu, E. T., Kim, W.-H., Park, H., Yang, H.-K., Kim, J.-I., Lee, C. |
| shingle_author_4 | Cho, S.-Y., Sung, C. O., Chae, J., Lee, J., Na, D., Kang, W., Kang, J., Min, S., Lee, A., Kwak, E., Kim, J., Choi, B., Kim, H., Chuang, J. H., Pak, H.-K., Park, C.-S., Park, S., Ko, Y. H., Lee, D., Roh, J., Cho, M.-S., Park, S., Ju, Y. S., Suh, Y.-S., Kong, S.-H., Lee, H.-J., Keck, J., Banchereau, J., Liu, E. T., Kim, W.-H., Park, H., Yang, H.-K., Kim, J.-I., Lee, C. |
| shingle_catch_all_1 | Alterations in the Rho pathway contribute to Epstein-Barr virus-induced lymphomagenesis in immunosuppressed environments Immunobiology and Immunotherapy, Lymphoid Neoplasia Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphomas (EBV + -DLBLs) tend to occur in immunocompromised patients, such as the elderly or those undergoing solid organ transplantation. The pathogenesis and genomic characteristics of EBV + -DLBLs are largely unknown because of the limited availability of human samples and lack of experimental animal models. We observed the development of 25 human EBV + -DLBLs during the engraftment of gastric adenocarcinomas into immunodeficient mice. An integrated genomic analysis of the human-derived EBV + -DLBLs revealed enrichment of mutations in Rho pathway genes, including RHPN2 , and Rho pathway transcriptomic activation. Targeting the Rho pathway using a Rho-associated protein kinase (ROCK) inhibitor, fasudil, markedly decreased tumor growth in EBV + -DLBL patient-derived xenograft (PDX) models. Thus, alterations in the Rho pathway appear to contribute to EBV-induced lymphomagenesis in immunosuppressed environments. Cho, S.-Y., Sung, C. O., Chae, J., Lee, J., Na, D., Kang, W., Kang, J., Min, S., Lee, A., Kwak, E., Kim, J., Choi, B., Kim, H., Chuang, J. H., Pak, H.-K., Park, C.-S., Park, S., Ko, Y. H., Lee, D., Roh, J., Cho, M.-S., Park, S., Ju, Y. S., Suh, Y.-S., Kong, S.-H., Lee, H.-J., Keck, J., Banchereau, J., Liu, E. T., Kim, W.-H., Park, H., Yang, H.-K., Kim, J.-I., Lee, C. American Society of Hematology (ASH) 0006-4971 00064971 1528-0020 15280020 |
| shingle_catch_all_2 | Alterations in the Rho pathway contribute to Epstein-Barr virus-induced lymphomagenesis in immunosuppressed environments Immunobiology and Immunotherapy, Lymphoid Neoplasia Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphomas (EBV + -DLBLs) tend to occur in immunocompromised patients, such as the elderly or those undergoing solid organ transplantation. The pathogenesis and genomic characteristics of EBV + -DLBLs are largely unknown because of the limited availability of human samples and lack of experimental animal models. We observed the development of 25 human EBV + -DLBLs during the engraftment of gastric adenocarcinomas into immunodeficient mice. An integrated genomic analysis of the human-derived EBV + -DLBLs revealed enrichment of mutations in Rho pathway genes, including RHPN2 , and Rho pathway transcriptomic activation. Targeting the Rho pathway using a Rho-associated protein kinase (ROCK) inhibitor, fasudil, markedly decreased tumor growth in EBV + -DLBL patient-derived xenograft (PDX) models. Thus, alterations in the Rho pathway appear to contribute to EBV-induced lymphomagenesis in immunosuppressed environments. Cho, S.-Y., Sung, C. O., Chae, J., Lee, J., Na, D., Kang, W., Kang, J., Min, S., Lee, A., Kwak, E., Kim, J., Choi, B., Kim, H., Chuang, J. H., Pak, H.-K., Park, C.-S., Park, S., Ko, Y. H., Lee, D., Roh, J., Cho, M.-S., Park, S., Ju, Y. S., Suh, Y.-S., Kong, S.-H., Lee, H.-J., Keck, J., Banchereau, J., Liu, E. T., Kim, W.-H., Park, H., Yang, H.-K., Kim, J.-I., Lee, C. American Society of Hematology (ASH) 0006-4971 00064971 1528-0020 15280020 |
| shingle_catch_all_3 | Alterations in the Rho pathway contribute to Epstein-Barr virus-induced lymphomagenesis in immunosuppressed environments Immunobiology and Immunotherapy, Lymphoid Neoplasia Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphomas (EBV + -DLBLs) tend to occur in immunocompromised patients, such as the elderly or those undergoing solid organ transplantation. The pathogenesis and genomic characteristics of EBV + -DLBLs are largely unknown because of the limited availability of human samples and lack of experimental animal models. We observed the development of 25 human EBV + -DLBLs during the engraftment of gastric adenocarcinomas into immunodeficient mice. An integrated genomic analysis of the human-derived EBV + -DLBLs revealed enrichment of mutations in Rho pathway genes, including RHPN2 , and Rho pathway transcriptomic activation. Targeting the Rho pathway using a Rho-associated protein kinase (ROCK) inhibitor, fasudil, markedly decreased tumor growth in EBV + -DLBL patient-derived xenograft (PDX) models. Thus, alterations in the Rho pathway appear to contribute to EBV-induced lymphomagenesis in immunosuppressed environments. Cho, S.-Y., Sung, C. O., Chae, J., Lee, J., Na, D., Kang, W., Kang, J., Min, S., Lee, A., Kwak, E., Kim, J., Choi, B., Kim, H., Chuang, J. H., Pak, H.-K., Park, C.-S., Park, S., Ko, Y. H., Lee, D., Roh, J., Cho, M.-S., Park, S., Ju, Y. S., Suh, Y.-S., Kong, S.-H., Lee, H.-J., Keck, J., Banchereau, J., Liu, E. T., Kim, W.-H., Park, H., Yang, H.-K., Kim, J.-I., Lee, C. American Society of Hematology (ASH) 0006-4971 00064971 1528-0020 15280020 |
| shingle_catch_all_4 | Alterations in the Rho pathway contribute to Epstein-Barr virus-induced lymphomagenesis in immunosuppressed environments Immunobiology and Immunotherapy, Lymphoid Neoplasia Epstein-Barr virus (EBV)-positive diffuse large B-cell lymphomas (EBV + -DLBLs) tend to occur in immunocompromised patients, such as the elderly or those undergoing solid organ transplantation. The pathogenesis and genomic characteristics of EBV + -DLBLs are largely unknown because of the limited availability of human samples and lack of experimental animal models. We observed the development of 25 human EBV + -DLBLs during the engraftment of gastric adenocarcinomas into immunodeficient mice. An integrated genomic analysis of the human-derived EBV + -DLBLs revealed enrichment of mutations in Rho pathway genes, including RHPN2 , and Rho pathway transcriptomic activation. Targeting the Rho pathway using a Rho-associated protein kinase (ROCK) inhibitor, fasudil, markedly decreased tumor growth in EBV + -DLBL patient-derived xenograft (PDX) models. Thus, alterations in the Rho pathway appear to contribute to EBV-induced lymphomagenesis in immunosuppressed environments. Cho, S.-Y., Sung, C. O., Chae, J., Lee, J., Na, D., Kang, W., Kang, J., Min, S., Lee, A., Kwak, E., Kim, J., Choi, B., Kim, H., Chuang, J. H., Pak, H.-K., Park, C.-S., Park, S., Ko, Y. H., Lee, D., Roh, J., Cho, M.-S., Park, S., Ju, Y. S., Suh, Y.-S., Kong, S.-H., Lee, H.-J., Keck, J., Banchereau, J., Liu, E. T., Kim, W.-H., Park, H., Yang, H.-K., Kim, J.-I., Lee, C. American Society of Hematology (ASH) 0006-4971 00064971 1528-0020 15280020 |
| shingle_title_1 | Alterations in the Rho pathway contribute to Epstein-Barr virus-induced lymphomagenesis in immunosuppressed environments |
| shingle_title_2 | Alterations in the Rho pathway contribute to Epstein-Barr virus-induced lymphomagenesis in immunosuppressed environments |
| shingle_title_3 | Alterations in the Rho pathway contribute to Epstein-Barr virus-induced lymphomagenesis in immunosuppressed environments |
| shingle_title_4 | Alterations in the Rho pathway contribute to Epstein-Barr virus-induced lymphomagenesis in immunosuppressed environments |
| timestamp | 2025-06-30T23:34:34.597Z |
| titel | Alterations in the Rho pathway contribute to Epstein-Barr virus-induced lymphomagenesis in immunosuppressed environments |
| titel_suche | Alterations in the Rho pathway contribute to Epstein-Barr virus-induced lymphomagenesis in immunosuppressed environments |
| topic | W WW-YZ |
| uid | ipn_articles_6245167 |